APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Rhabdomyosarcoma Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Rhabdomyosarcoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174032740322 December 2025195 pages

Choose your research edition.

Industry ResearchRhabdomyosarcoma Drug Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Rhabdomyosarcoma Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Rhabdomyosarcoma Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rhabdomyosarcoma Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Rhabdomyosarcoma Drug Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Rhabdomyosarcoma Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Rhabdomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rhabdomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rhabdomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Rhabdomyosarcoma Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Rhabdomyosarcoma Drug include Eisai Co Ltd, Novartis AG, Pfizer Inc, Bristol-Myers Squibb Co, Tarveda Therapeutics Inc, Taiwan Liposome Company Ltd, Taiho Pharmaceutical Co Ltd, Noxxon Pharma AG and NantKwest Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Rhabdomyosarcoma Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rhabdomyosarcoma Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rhabdomyosarcoma Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Rhabdomyosarcoma Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Rhabdomyosarcoma Drug Segment by Company

Eisai Co Ltd

Novartis AG

Pfizer Inc

Bristol-Myers Squibb Co

Tarveda Therapeutics Inc

Taiwan Liposome Company Ltd

Taiho Pharmaceutical Co Ltd

Noxxon Pharma AG

NantKwest Inc

MacroGenics Inc

Ipsen SA

Iproteos SL

Exelixis Inc

Epizyme Inc

Celgene Corp

Boehringer Ingelheim GmbH

Bellicum Pharmaceuticals Inc

Rhabdomyosarcoma Drug Segment by Type

ARI-4175

AT-69

Celyvir

Enoblituzumab

Axitinib

Crizotinib

Others

Rhabdomyosarcoma Drug Segment by Application

Clinic

Hospital

Research Center

Others

Rhabdomyosarcoma Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rhabdomyosarcoma Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rhabdomyosarcoma Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rhabdomyosarcoma Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rhabdomyosarcoma Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Rhabdomyosarcoma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Rhabdomyosarcoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Rhabdomyosarcoma Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Rhabdomyosarcoma Drug Industry Trends Table 2. Rhabdomyosarcoma Drug Industry Drivers Table 3. Rhabdomyosarcoma Drug Industry Opportunities and Challenges Table 4. Rhabdomyosarcoma Drug Industry Restraints Table 5. Global Rhabdomyosarcoma Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Rhabdomyosarcoma Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Rhabdomyosarcoma Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Rhabdomyosarcoma Drug Sales Market Share by Manufacturers Table 9. Global Rhabdomyosarcoma Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Rhabdomyosarcoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Rhabdomyosarcoma Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Rhabdomyosarcoma Drug Manufacturers, Product Type & Application Table 13. Global Rhabdomyosarcoma Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Rhabdomyosarcoma Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ARI-4175 Table 17. Major Manufacturers of AT-69 Table 18. Major Manufacturers of Celyvir Table 19. Major Manufacturers of Enoblituzumab Table 20. Major Manufacturers of Axitinib Table 21. Major Manufacturers of Crizotinib Table 22. Major Manufacturers of Others Table 23. Global Rhabdomyosarcoma Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Rhabdomyosarcoma Drug Sales by Type (2021-2026) & (k units) Table 25. Global Rhabdomyosarcoma Drug Sales by Type (2027-2032) & (k units) Table 26. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2026) Table 27. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2027-2032) Table 28. Global Rhabdomyosarcoma Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 29. Global Rhabdomyosarcoma Drug Revenue by Type (2021-2026) & (k units) Table 30. Global Rhabdomyosarcoma Drug Revenue by Type (2027-2032) & (k units) Table 31. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2026) Table 32. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Research Center Table 36. Major Manufacturers of Others Table 37. Global Rhabdomyosarcoma Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global Rhabdomyosarcoma Drug Sales by Application (2021-2026) & (k units) Table 39. Global Rhabdomyosarcoma Drug Sales by Application (2027-2032) & (k units) Table 40. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2026) Table 41. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2027-2032) Table 42. Global Rhabdomyosarcoma Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 43. Global Rhabdomyosarcoma Drug Revenue by Application (2021-2026) & (k units) Table 44. Global Rhabdomyosarcoma Drug Revenue by Application (2027-2032) & (k units) Table 45. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2026) Table 46. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2027-2032) Table 47. Global Rhabdomyosarcoma Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 48. Global Rhabdomyosarcoma Drug Sales by Region (2021-2026) & (k units) Table 49. Global Rhabdomyosarcoma Drug Sales Market Share by Region (2021-2026) Table 50. Global Rhabdomyosarcoma Drug Sales Forecasted by Region (2027-2032) & (k units) Table 51. Global Rhabdomyosarcoma Drug Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Rhabdomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 53. North America Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 54. North America Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 55. Europe Rhabdomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Europe Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 57. Europe Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 58. Asia Pacific Rhabdomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 59. Asia Pacific Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 60. Asia Pacific Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 61. South America, Middle East and Africa Rhabdomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 62. South America, Middle East and Africa Rhabdomyosarcoma Drug Sales by Country (2021-2026) & (k units) Table 63. South America, Middle East and Africa Rhabdomyosarcoma Drug Sales by Country (2027-2032) & (k units) Table 64. Global Rhabdomyosarcoma Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Rhabdomyosarcoma Drug Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Rhabdomyosarcoma Drug Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2021-2026) Table 68. Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2027-2032) Table 69. Eisai Co Ltd Company Information Table 70. Eisai Co Ltd Business Overview Table 71. Eisai Co Ltd Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Eisai Co Ltd Rhabdomyosarcoma Drug Product Portfolio Table 73. Eisai Co Ltd Recent Development Table 74. Novartis AG Company Information Table 75. Novartis AG Business Overview Table 76. Novartis AG Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Novartis AG Rhabdomyosarcoma Drug Product Portfolio Table 78. Novartis AG Recent Development Table 79. Pfizer Inc Company Information Table 80. Pfizer Inc Business Overview Table 81. Pfizer Inc Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Pfizer Inc Rhabdomyosarcoma Drug Product Portfolio Table 83. Pfizer Inc Recent Development Table 84. Bristol-Myers Squibb Co Company Information Table 85. Bristol-Myers Squibb Co Business Overview Table 86. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Product Portfolio Table 88. Bristol-Myers Squibb Co Recent Development Table 89. Tarveda Therapeutics Inc Company Information Table 90. Tarveda Therapeutics Inc Business Overview Table 91. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Product Portfolio Table 93. Tarveda Therapeutics Inc Recent Development Table 94. Taiwan Liposome Company Ltd Company Information Table 95. Taiwan Liposome Company Ltd Business Overview Table 96. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Product Portfolio Table 98. Taiwan Liposome Company Ltd Recent Development Table 99. Taiho Pharmaceutical Co Ltd Company Information Table 100. Taiho Pharmaceutical Co Ltd Business Overview Table 101. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Product Portfolio Table 103. Taiho Pharmaceutical Co Ltd Recent Development Table 104. Noxxon Pharma AG Company Information Table 105. Noxxon Pharma AG Business Overview Table 106. Noxxon Pharma AG Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Noxxon Pharma AG Rhabdomyosarcoma Drug Product Portfolio Table 108. Noxxon Pharma AG Recent Development Table 109. NantKwest Inc Company Information Table 110. NantKwest Inc Business Overview Table 111. NantKwest Inc Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. NantKwest Inc Rhabdomyosarcoma Drug Product Portfolio Table 113. NantKwest Inc Recent Development Table 114. MacroGenics Inc Company Information Table 115. MacroGenics Inc Business Overview Table 116. MacroGenics Inc Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. MacroGenics Inc Rhabdomyosarcoma Drug Product Portfolio Table 118. MacroGenics Inc Recent Development Table 119. Ipsen SA Company Information Table 120. Ipsen SA Business Overview Table 121. Ipsen SA Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Ipsen SA Rhabdomyosarcoma Drug Product Portfolio Table 123. Ipsen SA Recent Development Table 124. Iproteos SL Company Information Table 125. Iproteos SL Business Overview Table 126. Iproteos SL Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Iproteos SL Rhabdomyosarcoma Drug Product Portfolio Table 128. Iproteos SL Recent Development Table 129. Exelixis Inc Company Information Table 130. Exelixis Inc Business Overview Table 131. Exelixis Inc Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Exelixis Inc Rhabdomyosarcoma Drug Product Portfolio Table 133. Exelixis Inc Recent Development Table 134. Epizyme Inc Company Information Table 135. Epizyme Inc Business Overview Table 136. Epizyme Inc Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Epizyme Inc Rhabdomyosarcoma Drug Product Portfolio Table 138. Epizyme Inc Recent Development Table 139. Celgene Corp Company Information Table 140. Celgene Corp Business Overview Table 141. Celgene Corp Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Celgene Corp Rhabdomyosarcoma Drug Product Portfolio Table 143. Celgene Corp Recent Development Table 144. Boehringer Ingelheim GmbH Company Information Table 145. Boehringer Ingelheim GmbH Business Overview Table 146. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Product Portfolio Table 148. Boehringer Ingelheim GmbH Recent Development Table 149. Bellicum Pharmaceuticals Inc Company Information Table 150. Bellicum Pharmaceuticals Inc Business Overview Table 151. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Product Portfolio Table 153. Bellicum Pharmaceuticals Inc Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Rhabdomyosarcoma Drug Distributors List Table 157. Rhabdomyosarcoma Drug Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Rhabdomyosarcoma Drug Product Image Figure 2. Global Rhabdomyosarcoma Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rhabdomyosarcoma Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Rhabdomyosarcoma Drug Sales (2021-2032) & (k units) Figure 5. Global Rhabdomyosarcoma Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Rhabdomyosarcoma Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ARI-4175 Image Figure 9. AT-69 Image Figure 10. Celyvir Image Figure 11. Enoblituzumab Image Figure 12. Axitinib Image Figure 13. Crizotinib Image Figure 14. Others Image Figure 15. Global Rhabdomyosarcoma Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Rhabdomyosarcoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2032) Figure 18. Global Rhabdomyosarcoma Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Rhabdomyosarcoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. Research Center Image Figure 24. Others Image Figure 25. Global Rhabdomyosarcoma Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 26. Global Rhabdomyosarcoma Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2032) Figure 28. Global Rhabdomyosarcoma Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 29. Global Rhabdomyosarcoma Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2032) Figure 31. North America Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 32. North America Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 33. U.S. Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Canada Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Mexico Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 37. Europe Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 38. Germany Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. France Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. U.K. Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Italy Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Netherlands Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 44. Asia Pacific Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 45. China Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. Japan Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. South Korea Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. Southeast Asia Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. India Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. Australia Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 52. South America, Middle East and Africa Rhabdomyosarcoma Drug Sales Market Share by Country (2021-2032) Figure 53. Brazil Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. South Africa Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Saudi Arabia Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Turkey Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. Argentina Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. UAE Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 59. Egypt Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 60. Chile Rhabdomyosarcoma Drug Sales and Growth Rate (2021-2032) & (k units) Figure 61. Global Rhabdomyosarcoma Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Rhabdomyosarcoma Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 64. North America Rhabdomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 66. Europe Rhabdomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Rhabdomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Rhabdomyosarcoma Drug Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Rhabdomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Rhabdomyosarcoma Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Rhabdomyosarcoma Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • ARI-4175
  • AT-69
  • Celyvir
  • Enoblituzumab
  • Axitinib
  • Crizotinib
  • Others
Applications
  • Clinic
  • Hospital
  • Research Center
  • Others
Companies covered
  • Eisai Co Ltd
  • Novartis AG
  • Pfizer Inc
  • Bristol-Myers Squibb Co
  • Tarveda Therapeutics Inc
  • Taiwan Liposome Company Ltd
  • Taiho Pharmaceutical Co Ltd
  • Noxxon Pharma AG
  • NantKwest Inc
  • MacroGenics Inc
  • Ipsen SA
  • Iproteos SL
  • Exelixis Inc
  • Epizyme Inc
  • Celgene Corp
  • Boehringer Ingelheim GmbH
  • Bellicum Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Rhabdomyosarcoma Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Rhabdomyosarcoma Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Rhabdomyosarcoma Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Rhabdomyosarcoma Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Rhabdomyosarcoma Drug Market Dynamics
  1. 2.1 Rhabdomyosarcoma Drug Industry Trends
  2. 2.2 Rhabdomyosarcoma Drug Industry Drivers
  3. 2.3 Rhabdomyosarcoma Drug Industry Opportunities and Challenges
  4. 2.4 Rhabdomyosarcoma Drug Industry Restraints
3 Rhabdomyosarcoma Drug Market by Manufacturers
  1. 3.1 Global Rhabdomyosarcoma Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Rhabdomyosarcoma Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Rhabdomyosarcoma Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Rhabdomyosarcoma Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Rhabdomyosarcoma Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Rhabdomyosarcoma Drug Manufacturers, Product Type & Application
  7. 3.7 Global Rhabdomyosarcoma Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Rhabdomyosarcoma Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Rhabdomyosarcoma Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Rhabdomyosarcoma Drug Tier 1, Tier 2, and Tier 3
4 Rhabdomyosarcoma Drug Market by Type
  1. 4.1 Rhabdomyosarcoma Drug Type Introduction
  2. 4.1.1 ARI-4175
  3. 4.1.2 AT-69
  4. 4.1.3 Celyvir
  5. 4.1.4 Enoblituzumab
  6. 4.1.5 Axitinib
  7. 4.1.6 Crizotinib
  8. 4.1.7 Others
  9. 4.2 Global Rhabdomyosarcoma Drug Sales by Type
  10. 4.2.1 Global Rhabdomyosarcoma Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Rhabdomyosarcoma Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Rhabdomyosarcoma Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Rhabdomyosarcoma Drug Revenue by Type
  14. 4.3.1 Global Rhabdomyosarcoma Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Rhabdomyosarcoma Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Rhabdomyosarcoma Drug Revenue Market Share by Type (2021-2032)
5 Rhabdomyosarcoma Drug Market by Application
  1. 5.1 Rhabdomyosarcoma Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Research Center
  5. 5.1.4 Others
  6. 5.2 Global Rhabdomyosarcoma Drug Sales by Application
  7. 5.2.1 Global Rhabdomyosarcoma Drug Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Rhabdomyosarcoma Drug Sales by Application (2021-2032)
  9. 5.2.3 Global Rhabdomyosarcoma Drug Sales Market Share by Application (2021-2032)
  10. 5.3 Global Rhabdomyosarcoma Drug Revenue by Application
  11. 5.3.1 Global Rhabdomyosarcoma Drug Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Rhabdomyosarcoma Drug Revenue by Application (2021-2032)
  13. 5.3.3 Global Rhabdomyosarcoma Drug Revenue Market Share by Application (2021-2032)
6 Global Rhabdomyosarcoma Drug Sales by Region
  1. 6.1 Global Rhabdomyosarcoma Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rhabdomyosarcoma Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Rhabdomyosarcoma Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Rhabdomyosarcoma Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Rhabdomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Rhabdomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Rhabdomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Rhabdomyosarcoma Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Rhabdomyosarcoma Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Rhabdomyosarcoma Drug Revenue by Region
  1. 7.1 Global Rhabdomyosarcoma Drug Revenue by Region
  2. 7.1.1 Global Rhabdomyosarcoma Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Rhabdomyosarcoma Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Rhabdomyosarcoma Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Rhabdomyosarcoma Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Rhabdomyosarcoma Drug Revenue (2021-2032)
  8. 7.2.2 North America Rhabdomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Rhabdomyosarcoma Drug Revenue (2021-2032)
  11. 7.3.2 Europe Rhabdomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Rhabdomyosarcoma Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Rhabdomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Rhabdomyosarcoma Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Rhabdomyosarcoma Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eisai Co Ltd
  2. 8.1.1 Eisai Co Ltd Company Information
  3. 8.1.2 Eisai Co Ltd Business Overview
  4. 8.1.3 Eisai Co Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eisai Co Ltd Rhabdomyosarcoma Drug Product Portfolio
  6. 8.1.5 Eisai Co Ltd Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Rhabdomyosarcoma Drug Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Pfizer Inc
  14. 8.3.1 Pfizer Inc Company Information
  15. 8.3.2 Pfizer Inc Business Overview
  16. 8.3.3 Pfizer Inc Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Inc Rhabdomyosarcoma Drug Product Portfolio
  18. 8.3.5 Pfizer Inc Recent Developments
  19. 8.4 Bristol-Myers Squibb Co
  20. 8.4.1 Bristol-Myers Squibb Co Company Information
  21. 8.4.2 Bristol-Myers Squibb Co Business Overview
  22. 8.4.3 Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Co Rhabdomyosarcoma Drug Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Co Recent Developments
  25. 8.5 Tarveda Therapeutics Inc
  26. 8.5.1 Tarveda Therapeutics Inc Company Information
  27. 8.5.2 Tarveda Therapeutics Inc Business Overview
  28. 8.5.3 Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tarveda Therapeutics Inc Rhabdomyosarcoma Drug Product Portfolio
  30. 8.5.5 Tarveda Therapeutics Inc Recent Developments
  31. 8.6 Taiwan Liposome Company Ltd
  32. 8.6.1 Taiwan Liposome Company Ltd Company Information
  33. 8.6.2 Taiwan Liposome Company Ltd Business Overview
  34. 8.6.3 Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Taiwan Liposome Company Ltd Rhabdomyosarcoma Drug Product Portfolio
  36. 8.6.5 Taiwan Liposome Company Ltd Recent Developments
  37. 8.7 Taiho Pharmaceutical Co Ltd
  38. 8.7.1 Taiho Pharmaceutical Co Ltd Company Information
  39. 8.7.2 Taiho Pharmaceutical Co Ltd Business Overview
  40. 8.7.3 Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Taiho Pharmaceutical Co Ltd Rhabdomyosarcoma Drug Product Portfolio
  42. 8.7.5 Taiho Pharmaceutical Co Ltd Recent Developments
  43. 8.8 Noxxon Pharma AG
  44. 8.8.1 Noxxon Pharma AG Company Information
  45. 8.8.2 Noxxon Pharma AG Business Overview
  46. 8.8.3 Noxxon Pharma AG Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Noxxon Pharma AG Rhabdomyosarcoma Drug Product Portfolio
  48. 8.8.5 Noxxon Pharma AG Recent Developments
  49. 8.9 NantKwest Inc
  50. 8.9.1 NantKwest Inc Company Information
  51. 8.9.2 NantKwest Inc Business Overview
  52. 8.9.3 NantKwest Inc Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 NantKwest Inc Rhabdomyosarcoma Drug Product Portfolio
  54. 8.9.5 NantKwest Inc Recent Developments
  55. 8.10 MacroGenics Inc
  56. 8.10.1 MacroGenics Inc Company Information
  57. 8.10.2 MacroGenics Inc Business Overview
  58. 8.10.3 MacroGenics Inc Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MacroGenics Inc Rhabdomyosarcoma Drug Product Portfolio
  60. 8.10.5 MacroGenics Inc Recent Developments
  61. 8.11 Ipsen SA
  62. 8.11.1 Ipsen SA Company Information
  63. 8.11.2 Ipsen SA Business Overview
  64. 8.11.3 Ipsen SA Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Ipsen SA Rhabdomyosarcoma Drug Product Portfolio
  66. 8.11.5 Ipsen SA Recent Developments
  67. 8.12 Iproteos SL
  68. 8.12.1 Iproteos SL Company Information
  69. 8.12.2 Iproteos SL Business Overview
  70. 8.12.3 Iproteos SL Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Iproteos SL Rhabdomyosarcoma Drug Product Portfolio
  72. 8.12.5 Iproteos SL Recent Developments
  73. 8.13 Exelixis Inc
  74. 8.13.1 Exelixis Inc Company Information
  75. 8.13.2 Exelixis Inc Business Overview
  76. 8.13.3 Exelixis Inc Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Exelixis Inc Rhabdomyosarcoma Drug Product Portfolio
  78. 8.13.5 Exelixis Inc Recent Developments
  79. 8.14 Epizyme Inc
  80. 8.14.1 Epizyme Inc Company Information
  81. 8.14.2 Epizyme Inc Business Overview
  82. 8.14.3 Epizyme Inc Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Epizyme Inc Rhabdomyosarcoma Drug Product Portfolio
  84. 8.14.5 Epizyme Inc Recent Developments
  85. 8.15 Celgene Corp
  86. 8.15.1 Celgene Corp Company Information
  87. 8.15.2 Celgene Corp Business Overview
  88. 8.15.3 Celgene Corp Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Celgene Corp Rhabdomyosarcoma Drug Product Portfolio
  90. 8.15.5 Celgene Corp Recent Developments
  91. 8.16 Boehringer Ingelheim GmbH
  92. 8.16.1 Boehringer Ingelheim GmbH Company Information
  93. 8.16.2 Boehringer Ingelheim GmbH Business Overview
  94. 8.16.3 Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Boehringer Ingelheim GmbH Rhabdomyosarcoma Drug Product Portfolio
  96. 8.16.5 Boehringer Ingelheim GmbH Recent Developments
  97. 8.17 Bellicum Pharmaceuticals Inc
  98. 8.17.1 Bellicum Pharmaceuticals Inc Company Information
  99. 8.17.2 Bellicum Pharmaceuticals Inc Business Overview
  100. 8.17.3 Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Bellicum Pharmaceuticals Inc Rhabdomyosarcoma Drug Product Portfolio
  102. 8.17.5 Bellicum Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Rhabdomyosarcoma Drug Value Chain Analysis
  2. 9.1.1 Rhabdomyosarcoma Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Rhabdomyosarcoma Drug Production Mode & Process
  6. 9.2 Rhabdomyosarcoma Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Rhabdomyosarcoma Drug Distributors
  9. 9.2.3 Rhabdomyosarcoma Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst